In a phase III study of women with HER2-positive breast cancer that treated with trastuzumab, the combination therapy with capecitabine and the multi-tyrosine kinase inhibitor lapatinib, which inhibits both HER2 and EGFR, substantially extended progression-free survival time for 4 months [38]. Here, ERBB2 is linked to breast cancer.